Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer’s Disease
- Researchers from the Nature Cell Co. are currently completing trials to test the safety and efficacy of using stem cells as a treatment for dementia. Patients will be randomly put into placebo or treatment groups and will receive an IV of either placebo or adipose tissue derived mesenchymal stem cells 9 times at 2-week intervals. The patients will then return at weeks 30 and 52 for follow-up appointments. At these appointments, the patients will be monitored for any adverse effects and will also be given multiple cognitive functioning tests and have their score compared to their baseline score prior to treatment. Eligible patients must have diagnosed dementia due only to Alzheimer’s, must have no abnormal screening laboratory values, must have no history of seizures, and must have any other neurodegenerative disease. Please visit the clinical trials website for more information.
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer’s Disease
- Researchers at Hope Biosciences are completing trials to test the safety and efficacy of their mesenchymal stem cells as a treatment for Alzheimer’s. The patients of these trials will receive 4 intravenous infusions at 2-week intervals and then will be monitored for 1 year following treatment. The patients will have received 200 million HB-adMSC cells by the end of treatment. The post-treatment monitoring will involve testing for blood levels of various biological molecules in order to monitor safety and will also involve taking cognitive studies and comparing the score to a pre-treatment baseline. The treatment will be tested for efficacy by monitoring any changes in Alzheimer’s disease-related inflammation. Please visit the clinical trials website for more information.
Allogenic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease
- Researchers from Longeveron LLC are completing trials to test the safety and efficacy of LMSC’s (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed Alzheimer’s disease. The patients in these trials will intravenously receive either a placebo, a low dose (20 Million LMSCs) of LMSCs, or a high dose (100 million LMScs) of LMSCs. Following treatment, the patients will have 6 follow up appointments for a year that involve monitoring any adverse effects as well as looking at biomarkers for improvement and taking cognitive assessments to compare to a baseline score from before the patients received treatment. Dementia caused by any other degenerative disease besides Alzheimer’s is criteria for exclusion from this trial. Patients can be deemed ineligible for a multitude of other factors including compounding conditions as well as prior participation in similar trials. Please visit the clinical trials website for more information.
Alzheimer’s and Cognitive Impairment Stem Cell Treatment
- Administering bone marrow stem cells in animal models demonstrated repaired cognitive functioning in tested animals. The study will continue to go on until the 4th of October 2022. Results concluded that there is enormous promise but stem cell therapy is still underdeveloped. The researchers suggested models with higher-order animals that more faithfully mimic clinical and neurodegenerative features of humans.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427593/table/Tab1/?report=objectonly shows a table of studies done for rodent stem cell transplantation over the past five years.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427593/table/Tab2/?report=objectonly shows a table for ongoing stem cell trials done in humans with Alzheimer’s disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427593/ gives the full article on stem cell therapy for Alzheimer’s Disease in comparison with rodent modeling.